Evidence map›Paper›PMID 41081891›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026

Treatment outcomes of switching to aflibercept 8 mg in previously-treated neovascular age-related macular degeneration.

Keiko Kataoka, Koji Tanaka, Junichiro Honjyo, Yasunori Miyara, Nozomu Hashiya, Yuto Watanabe, Akiko Yamamoto, Yu Wakatsuki, Ayaka Nakai, Ryo Mukai and 11 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Keiko KataokaDepartment of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan. keiko-kataoka@ks.kyorin-u.ac.jp.ORCID 0000-0002-8795-6536
Koji TanakaDepartment of Ophthalmology, Nihon University School of Medicine, Tokyo, Japan.
Junichiro HonjyoDepartment of Ophthalmology, Fukushima Medical University, Fukushima, Japan.
Yasunori MiyaraDepartment of Ophthalmology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
Nozomu HashiyaDepartment of Ophthalmology, Tokyo Women's Medical University, Tokyo, Japan.
Yuto WatanabeDepartment of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan.
Akiko YamamotoDepartment of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan.
Yu WakatsukiDepartment of Ophthalmology, Nihon University School of Medicine, Tokyo, Japan.
Ayaka NakaiDepartment of Ophthalmology, Nihon University School of Medicine, Tokyo, Japan.
Ryo MukaiDepartment of Ophthalmology, Fukushima Medical University, Fukushima, Japan.
Yutaka KatoDepartment of Ophthalmology, Fukushima Medical University, Fukushima, Japan.
Nobuhiro TeraoDepartment of Ophthalmology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
Marina MaehiraDepartment of Ophthalmology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
Ichiro MarukoDepartment of Ophthalmology, Tokyo Women's Medical University, Tokyo, Japan.
Moeko KawaiDepartment of Ophthalmology, Tokyo Women's Medical University, Tokyo, Japan.
Tomohiro IidaDepartment of Ophthalmology, Tokyo Women's Medical University, Tokyo, Japan.
Hideki KoizumiDepartment of Ophthalmology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
Tetsuju SekiryuDepartment of Ophthalmology, Fukushima Medical University, Fukushima, Japan.
Ryusaburo MoriDepartment of Ophthalmology, Nihon University School of Medicine, Tokyo, Japan.
Annabelle A OkadaDepartment of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan.
Japan AMD Research Consortium (JARC)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate outcomes of switching to aflibercept 8 mg in eyes with neovascular age-related macular degeneration (nAMD) previously treated with anti-vascular endothelial growth factor (VEGF) agents.

methodsThis multicenter retrospective study examined 6-month treatment outcomes in eyes with nAMD previously treated and switched to aflibercept 8 mg. Data including best-corrected visual acuity (BCVA), number of previous injections, and treatment intervals were collected. Central retinal thickness (CRT), subfoveal choroidal thickness (SFCT), and maximal pigment epithelial detachment (PED) height were measured on optical coherence tomography images.

resultsAnalysis included 121 eyes (117 patients). Median number of previous anti-VEGF injections was 31.0 (interquartile range [IQR]: 20.5–55.5); median pre-switch interval was 5.0 (IQR: 4.0–8.0) weeks. At 6 months, 71 eyes (59%) continued aflibercept 8 mg and 50 (41%) discontinued due to worsening at intervals ≥ 8 weeks. The discontinued group had significantly shorter pre-switch intervals (4.0 [IQR: 4.0–5.0] vs. 6.0 [IQR: 5.0–8.0], P < 0.01) and thinner SFCT compared to the continued group (153 [IQR: 100–209] vs. 189 [IQR: 141–284], P = 0.012). At 6 months, CRT and PED decreased from 258 (IQR: 203–329) to 239 (IQR: 198–304) µm (P = 0.015) and from 195 (IQR: 112–293) to 164 (IQR: 82–263) µm (P = 0.007). BCVA was maintained (0.15 [IQR: 0.00–0.30] to 0.10 [IQR: 0.00–0.30]), P = 0.426). The median increase in injection interval was 2.0 (IQR: 1.0–3.5) weeks in continued eyes.

conclusionSwitching to aflibercept 8 mg may be an option to extend injection intervals, leading to a reduction in treatment burden.

Indexed as

Drug SubstitutionReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVisual AcuityWet Macular DegenerationAgedAged, 80 and overAngiogenesis InhibitorsDose-Response Relationship, DrugFemaleFluorescein AngiographyFollow-Up StudiesFundus OculiHumansIntravitreal InjectionsMaleafliberceptAngiogenesis InhibitorsReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor AAflibercept 8 mgAnti-vascular endothelial growth factor therapyNeovascular age-related macular degenerationSwitching

Identifiers

PMID41081891

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.